Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.

NCT07260513 is registered in ClinicalTrials.gov with Suzhou Genhouse Bio Co., Ltd. as lead sponsor.

NCT NCT07260513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07260513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
Lead sponsor
Suzhou Genhouse Bio Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 27, 2025
Completion date
December 31, 2030
Enrollment
126 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor cancer